Results 81 to 90 of about 26,238 (200)

Oligonucleotides as Radiopharmaceuticals

, 2006
Oligonucleotide radiopharmaceuticals is a slowly but steadily progressing field. With a panel of labeling and imaging techniques mastered by several groups, imaging of oligonucleotides is now relatively accessible and will be applied to more and more trials of oligonucleotide pharmacology.
openaire   +2 more sources

Evaluation of resazurin phenoxazine dye as a highly sensitive cell viability potency assay for natural killer cell‐derived extracellular vesicle‐based cancer biotherapeutics

Journal of Extracellular Biology
Natural killer cell‐derived extracellular vesicles (NK‐EVs) are candidate biotherapeutics against various cancers. However, standardised potency assays are necessary for a reliable assessment of NK‐EVs' cytotoxicity.
Frederic St‐Denis‐Bissonnette, Shirley Qiu, Sarah E. Cummings, Melanie Kirkby, Yohannes Haile, Sarah Wassmer, Gauri Muradia, Jelica Mehic, Andrew Stalker, Amit Shrestha, Michele Ardolino, Seung‐Hwan Lee, Dylan Burger, Lisheng Wang, Jessie R. Lavoie   +14 more
doaj   +1 more source

Radiopharmaceutical-induced bystander effect

, 2007
Indirect effects may contribute to the efficacy of radiotherapy by sterilizing malignant cells that are not directly irradiated. However, little is known of the influence of indirect effects in targeted radionuclide treatment.
Zalutsky, Michael R, Fullerton, Natasha E, Mairs, Robert J, Boyd, Marie   +3 more
core   +3 more sources

Structure–activity relationship of 18F-labeled PD-L1-targeting small molecule ligands: impact of radiolabeling strategy on affinity and in vivo performance

EJNMMI Radiopharmacy and Chemistry
Background Immune checkpoint inhibitor therapy addressing the PD-1/PD-L1 axis is a promising approach in cancer treatment. A clinically suitable radiotracer would allow molecular imaging of the temporospatial changes in tumor PD-L1 expression. This could
Fabian Krutzek, Cornelius K. Donat, Sven Stadlbauer   +2 more
doaj   +1 more source

Multifactorial analysis of radiochemical purity in high-activity 177Lu-labeled theranostics: impact of precursor source, 177Lu form, and production parameters

EJNMMI Radiopharmacy and Chemistry
Background Lutetium-177 (177Lu) theranostics have revolutionized personalized cancer treatment, particularly with FDA-approved therapies like [177Lu]Lu-DOTA-TATE for neuroendocrine tumors and [177Lu]Lu-PSMA for prostate cancer.
William Hunt, Mathew Long, Usama Kamil, Sunil Kellapatha, Wayne Noonan, Peter D. Roselt, Nathan Papa, Brittany Emmerson, Michael S. Hofman, Mohammad B. Haskali   +9 more
doaj   +1 more source

Current State of Radiolabeled Heterobivalent Peptidic Ligands in Tumor Imaging and Therapy

, 2020
Over the past few years, an approach emerged that combines different receptor-specific peptide radioligands able to bind different target structures on tumor cells concomitantly or separately.
Diana Braun, Björn Wängler, Carmen Wängler, Benedikt Judmann, Gert Fricker, Ralf Schirrmacher   +5 more
core   +1 more source

Radiopharmacologist’s and Radiochemist’s View on Targeting the Eph/Ephrin Receptor Tyrosine Kinase System

ACS Omega, 2020
Christin Neuber, Birgit Belter, Constantin Mamat, Jens Pietzsch   +3 more
doaj   +1 more source

Radiopharmaceutical transport in solid tumors via a 3-dimensional image-based spatiotemporal model

npj Systems Biology and Applications
Lutetium-177 prostate-specific membrane antigen (177Lu-PSMA)-targeted radiopharmaceutical therapy is a clinically approved treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).
Anahita Piranfar, Farshad Moradi Kashkooli, Wenbo Zhan, Ajay Bhandari, Babak Saboury, Arman Rahmim, M. Soltani   +6 more
doaj   +1 more source

Targeting Cancer Stem Cells with Radioimmunotherapy: The Case of the Ovarian Cancer Stemness-Associated Biomarker L1CAM

International Journal of Translational Medicine
Cancer stem cells (CSCs) are a dynamic population of tumor cells characterized by long-term self-renewal, high tumorigenicity, resistance to conventional therapies such as radio- and chemotherapy, and capacity to recapitulate the tumor heterogeneity ...
Tihomir Zh. Todorov, Roger Schibli, Martin Béhé, Jürgen Grünberg   +3 more
doaj   +1 more source

Optimized production of 89Zr as a medical radioisotope on a variable energy cyclotron and external beam-line

EJNMMI Physics
Background Zirconium-89 (89Zr) is a highly valued diagnostic radionuclide for positron emission tomography (PET) due to its long physical half-life of 78.4 h and decay characteristics, being preferred for the radiolabelling of nanoparticles and slow ...
Diana Cocioabă, Simona Baruta, Liviu Crăciun, Radu Leonte, Andrei Necsoiu, Maria-Roxana Tudoroiu-Cornoiu, Alexandru Jipa, Dana Niculae   +7 more
doaj   +1 more source